The National Health Surveillance Agency (Anvisa) has granted sanitary authorization for another medicinal product based on Cannabis in Brazil. The new permission was granted to the company Ephar Pesquisa e Desenvolvimento LTDA. for the commercialization of its Cannabidiol in two concentrations.

The decision was formalized in the Official Gazette through Resolution-RE No. 3,976, of October 9, 2025. The authorized products are Cannabidiol Ephar 50 mg/mL and Cannabidiol Ephar 100 mg/mL. Both formulations comply with the guidelines of RDC 327/2019, which establishes the criteria for the commercialization of products of this kind for medicinal purposes in the country.

The authorization is specific to formulas with tetrahydrocannabinol (THC) content of up to 0.2%. The products will be presented in an oral solution (drops), in 30 ml bottles, to facilitate administration to patients.